


Hepatotoxicity observed in clinical trials of aplaviroc (APL, 873140)

WG Nichols¹, <u>HM Steel¹</u>, TM Bonny¹, SS Min¹, L Curtis¹, K Kabeya², N Clumeck² ¹GlaxoSmithKline, Research Triangle Park, USA; ²CHU-Saint-Pierre, Brussels, Belgium.

Aplaviroc (APL, 873140, Ono 4128)

Specific CCR5 antagonist



- Potent HIV entry inhibitor
 - mean 1.66 log₁₀ decline at nadir in HIV-RNA after 10d monotherapy¹
- Safety profile supported further study in humans

¹ Lalezari J et al. AIDS 2005;19:1443–1448.

Aplaviroc Phase 2b Program



CCR100136

- 195 treatment-naïve subjects randomized to
 - APL 200mg BID / LPV/r
 - APL 400mg BID / LPV/r
 - APL 800mg QD / LPV/r
 - LPV/r / Combivir
 - 2:2:2:1 randomization




CCR102881

- 147 treatment-naïve subjects randomized to
 - APL 600mg BID / Combivir
 - APL 800mg BID / Combivir
 - Combivir / efavirenz
 - 2:2:1 randomisation

Sentinel case: Severe hepatitis

- 39 year old HIV+ male
 - CD4 283 cells/mm³
 - HBV/HCV negative
 - Normal AST/ALT/bilirubin
- APL 800mg BID + COM
- Day 59: developed severe hepatic cytolysis
- Liver biopsy:
 - Chronic inflammatory infiltrate, mod intensity



Liver biopsy (portal area)

Consistent with drug-induced hepatotoxicity

CCR102881 Individual Patient LFT Plots ALP •••• ALT AST BILT CK 70 60 LFT Values (x ULN) 50 40 30 **APL RX** 20 10 0 -50 -30 -20 -10 10 20 30 40 50 60 70 80 90 100 -40 0

Study Day

Review of Liver Enzyme Elevations in APL Phase IIb trials

- 336 subjects received treatment
 - 282 subjects on APL
 - median duration of therapy: 13 wks
- Central Lab database query to identify
 - any Grade 3/4 elevation in ALT, AST or bilirubin
- 13 subjects identified
 - 3 BL abnormalities (2 APL, 1 control) improved
 - 10 treatment-emergent cases, all on APL

Cases of Grade 3/4 Liver Enzyme Elevations NOT Attributed to APL (N=6)

- 3 cases: exercise induced
 - transient AST with concurrent elevation in CPK
- 2 cases: increased bilirubin related to other drugs
 - 1 after APL withdrawal and switch to ATZ/rtv
 - (max 5X ULN)
 - 1 with concomitant prochlorperazine and alcohol
 - (max 3X ULN)
- 1 case: grade 2 bilirubin at screen
 - fluctuations on APL
 - grade 3 at single time point, max 2.7X ULN

Cases of Clinical Concern (N=4)

- 1. Severe hepatitis
 - sentinel case (APL 800mg BID + COM)
 - reported as Serious Adverse Event (SAE)
- 2. Hepatitis
 - underlying hepatic disease (APL 400mg BID + LPV/r)
 - symptomatic ↑ in ALT (12x ULN) and bilirubin (3x ULN)
- 3. Asymptomatic hepatitis
 - no underlying liver disease (APL 400mg BID + LPV/r)
 - elevations in ALT/AST (max 9X ULN) without elevation in bilirubin
 - positive de-challenge and re-challenge
- 4. Hyperbilirubinaemia
 - HBV co-infected subject (APL 200mg BID + LPV/r)
 - Grade 3 elevations in bilirubin (max 5X ULN)
 - reported as SAE

Actions Taken to Protect Patient Safety


- Risk:benefit deemed unfavourable for therapy naïves
 - investigators notified
 - all subjects in Phase 2b studies stopped dosing
 - studies amended to collect additional follow-up data
- Ongoing phase 3 studies in treatment-experienced subjects (on OBT with APL 400mg BID or Placebo)
 - Screening and randomisation halted
 - Subjects already randomised (N=46) allowed to continue
 - few treatment options
 - intensive 2 weekly monitoring after re-consent of all subjects

APL Phase 3 Safety Findings

- 1 of 26 subjects randomized to APL developed grade 4 ALT at Week 4
 – max 24X ULN
 - - background ATV/r therapy
 - 57-year-old Caucasian man
 - asymptomatic at all visits
 - stopped all study medication

CCR104458

APL Phase 3 Safety Findings Individual Patient LFT Plots




APL Phase 3 Safety Response

Phase 3 studies terminated; treatment unblinded

 Subjects on APL, deemed to be gaining clinical benefit, allowed to continue Tx with intensive 2 weekly monitoring

"Hy's Law"

- 10-50% patients with <u>hepatocellular</u> jaundice will have fatal liver failure¹
- ALT <u>or</u> total bilirubin are relatively common (particularly in HIV/AIDS)
 - BUT <u>combination</u> is rare in drug development
- FDA: combination of "ALT >3xULN and total bilirubin >1.5xULN" as an indicator of clinical concern²



Hyman Zimmerman

- Clinical relevance validated:
 - 12.7% incidence of mortality/liver transplantation in subjects with hepatocellular jaundice³

¹Zimmerman HJ. <u>Hepatotoxicity</u> (New York: Appleton-Century Crofts), 1978. ²FDA, <u>www.fda.gov/cder/livertox/clinical.pdf-04-17-2001</u> ³Bjornsson and Olsson, Hepatology 2005;42:481-9.

Summary: Observations of Hepatotoxicity in APL Clinical Trials

- 4 of 308 (1%) subjects dosed with APL had combined elevations in ALT (>3xULN) and bilirubin (>1.5xULN), meeting Hy's Law criteria
- No deaths or cases of liver failure

 all subjects have fully recovered
- Clinical development of APL has been discontinued

Acknowledgements

- Investigators
- Sites/Patients involved in APL Clinical Program
- Chris Hunt and GSK Hepatotoxicity board
- External consultants (Watkins, Lewis, Kaplowitz)
- Aplaviroc Development Team

"Hepatotoxicity has been the most common single adverse effect.....causing major drug problems, including withdrawals and refusals to approve"

-Bob Temple, FDA CDER, 2002